Galloyl-Mediated Antigen Capture Coupled with Hypoxia-Responsive Reprogramming Drives Potent Photoimmunotherapy

Area of Science:

• Nanomedicine
• Cancer Immunology
• Biotechnology

Background:

• In situ cancer nanovaccines face challenges with tumor heterogeneity, antigen degradation, and inefficient cross-presentation.
• Existing methods like covalent conjugation have limitations in antigen capture breadth and quantity.

Purpose of the Study:

• To develop novel antigen-capturing liposomes (L-GA/INC/PPa) using gallic acid-derived polyphenolic lipids for enhanced antigen preservation.
• To investigate the synergistic effects of these nanovaccines with photodynamic therapy (PDT) for improved cancer treatment.

Main Methods:

• Construction of gallic acid-derived polyphenolic lipid-based liposomes (L-GA/INC/PPa) for noncovalent antigen capture.
• Combination therapy involving L-GA/INC/PPa nanovaccines and photodynamic therapy (PDT).
• Evaluation of antigen capture, dendritic cell activation, T cell infiltration, and tumor suppression in melanoma models.

Main Results:

• Noncovalent galloyl groups demonstrated superior antigen capture compared to covalent maleimide conjugation.
• The L-GA/INC/PPa nanovaccine combined with PDT significantly enhanced antigen capture, dendritic cell activation, and T cell infiltration.
• PDT-induced hypoxia activated an indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor prodrug, reducing regulatory T cell expansion.
• The dual-modality nanovaccine achieved potent suppression of both primary and distant tumors.

Conclusions:

• Gallic acid-derived polyphenolic lipids effectively capture a broad spectrum of tumor antigens, overcoming limitations of previous methods.
• The integration of antigen presentation and hypoxia-responsive immunosuppression reversal offers a potent dual-modality cancer nanovaccine strategy.
• This nanovaccine approach demonstrates significant potential for overcoming tumor heterogeneity and enhancing immunotherapy efficacy.